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ZINC DIFFERENTIALLY MODULATES DNA DAMAGE INDUCED 
BY ANTHRACYCLINES IN NORMAL AND CANCER CELLS
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Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 
Lodz 90-236, Poland
Zinc is one of the most essential trace elements in human organism. Low blood level of zinc is often noted in acute lymphocytic leukemia 
(ALL). Treatment with zinc adjuvant is hypothesized to accelerate recovery from ALL, and in conjunction with chemotherapy, cure 
ALL. Aim: We determined the effect of zinc on DNA damage induced by doxorubicin and idarubicin, two anthracyclines used in ALL 
treatment. Methods: The experiment was performed on acute lymphoblastic leukemia cell line (CCRF-CEM) and lymphocytes from 
peripheral blood of healthy, adult subjects. To evaluate the level of DNA damage the comet assay in the alkaline version was used. Results: 
We observed a significant difference in DNA damage level between normal and cancer cells in the presence of zinc. Cancer cells exhib-
ited a significant increase of DNA damage in the presence of zinc, while in lymphocytes no such effect was observed. Conclusion: Our 
results suggest that zinc may protect normal cells against DNA-damaging action of anthracyclins and increase this action in cancer cells.
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Zinc �elongs to essential microelements in human 
organism. It plays a significant role in many physiological 
processes including neuronal function� wound healing� 
immunity or growth and development. At the cellular 
level zinc plays an important role in such fundamental 
processes as cell proliferation� �NA meta�olism and 
repair� oxidative defense and cellular signaling path-
ways. It is a component of thousand of protein domains� 
including hundreds of zinc-containing enzymes and also 
many transcription factors [�� �]. Zinc within the cell 
is under precise regulation and majority of it is �ound 
to a num�er of proteins. The excess of free �la�ile� in-
tracellular zinc may distur� essential molecular events� 
including protein folding [�� �]. On the other hand� zinc 
deficiency may distur� cell oxidation status� deregulate 
mitochondrial functions� interfere with �NA repair and 
contri�ute to cancer induction and development [5� 6]. 
Zinc may also play an important role in healthy aging [�]. 
A decrease in zinc level in lymphocytes of elderly was 
o�served to �e with an increased level of oxidized pro-
teins and a lower expression of anti-oxidative enzymes 
[8]. Restoration of zinc level reversed these unfavora�le 
correlations.
The distur�ance in zinc meta�olism has �een rec-
ognized in the pathogenesis of leukemias since �9�9. 
E�y [9] descri�ed a �-year-old girl� which o�tained 
zinc at a rate of �.�8 mg/kg �ody weight/day� from the 
start of chemotherapy through � years of maintenance 
therapy. That treatment resulted in �one marrow remis-
sion from more than 95% to zero �last cell count in �oth 
hips within the first �� days of treatment� which never 
relapsed. In addition to the reduction of �last cells� red 
�lood cell production and other hemopoietic functions 
returned to normal at a clinically remarka�le rate. There 
were no side effects of zinc or chemotherapy at any 
time� and zinc was hypothesized to have improved 
the patient’s overall a�ility to withstand toxic effects 
of chemotherapy. Identical results occurred in �� other 
children with ALL whose parents chose therapy with zinc 
adjuvant. This report identifies zinc treatment as �eing 
vital to rapid and permanent recovery from ALL [9]. Now 
no modern chemotherapy� with the exception of the 
Polish trial [��]� includes zinc adjuvant even though zinc 
serum levels are usually low in leukemic children [9].
�oxoru�icin and idaru�icin are anthracyclines used 
as chemotherapeutic drugs in the effective treatment 
of a �road spectrum of leukemias and solid tumors 
[��� ��]. However� �oth doxoru�icin and idaru�icin 
have serious side effects� as �rain damage� growth and 
development delay or cardiomyopathy [��]. Cardiotox-
icity of anthracyclines is caused �y a generation of ROS 
�reactive oxygen species�� possi�ly with participation 
of iron ions or long-lived secondary alcohol meta�o-
lites [��� �5]. Free radicals and iron can damage cell 
mem�ranes increasing its permea�ility and interact 
with macromolecules inside the cell. Cardiac cells are 
especially suscepti�le to free radical damage �ecause 
of their high oxidative meta�olism and relatively poor 
antioxidant defense. Moreover� anthracyclines have 
a very high affinity for cardiolipin� a phospholipid in the 
inner mitochondrial mem�rane resulting in anthracy-
clines accumulating inside cardiac cells [�6]. Because 
of the side effects of anthracycline chemotherapy� 
many compounds are tested as potentially protective 
agents such as amifostine� dexrazoxane� selenium� 
vitamins E� A and C and memantine [�6��8]. �oxoru�i-
cin and idaru�icin exert their cytostatic effect �y direct 
and indirect interaction with �NA [��� �9���]. In the 
present work we determined the modulation of the 
�NA-damaging effect of these drugs �y zinc in normal 
lymphocytes and CCRF-CEM cells.
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phate-buffered saline; ROS — reactive oxygen species; S.E.M. — 
the average error of the mean.
Exp Oncol ����
��� �� �������
��8 Experimental Oncology ��� �������� ���� ��ecem�er�
MATERIALS AND METHODS
Chemicals. RPMI �6�� medium� streptomycin 
and penicillin� normal melting point �NMP� and low 
melting point �LMP� agarose� phosphate-�uffered 
saline �PBS�� �API ��’�6-diamino-�-phenylindole�� 
hydrogen peroxide �H�O�� and histopaque ���� were 
purchased from Sigma-Aldrich Co �St Louis� MO� 
USA�. Fetal �ovine serum �FSB� and L-glutamine was 
o�tained from GIBCO. �oxoru�icin� idaru�icin and zinc 
salts — ZnCl� and ZnSO� were from Sigma-Aldrich Co 
�St. Louis� MO� USA�. All chemicals were of the highest 
commercial grade availa�le.
Cell culture. The human ALL cell line �CCRF-CEM� 
was grown in RPMI �6�� medium supplemented 
with ��% heat-inactivated fetal �ovine serum �FBS�� 
� mM L-glutamine� penicillin ���� U/ml� and strepto-
mycin ���� µg/ml� in the presence of a 5% CO� atmo-
sphere at ��ºC.
Isolation of lymphocytes. Lymphocytes were 
isolated from peripheral �lood of male healthy do-
nors at the age �etween �� and �5 �y centrifugation 
in a density gradient of histopaque ���� ��5 min� 
�8� × g� �°C�. Each experiment was performed 
on �lood o�tained from an individual donor. The pel-
let containing lymphocytes was washed twice in PBS 
and resuspended in RPMI �6�� medium to give a�out 
� × ��5 cells per ml and further processed. The study 
was approved �y Ethic Committee of Medical Univer-
sity of Lodz.
Cell viability. The via�ility of the cells� lympho-
cytes and CCRF-CEM cells� was determined �y trypan 
�lue exclusion assay. The cells were incu�ated for 
� h at ��°C with doxoru�icin at concentration from the 
range �.�5�� µM and with idaru�icin at concentration 
from the range �.���� µM� washed and suspended 
in RPMI �6�� medium. An equal volume of �.�% trypan 
�lue reagent was added to the cell suspension and the 
percentage of via�le cells was evaluated under a field 
microscope. Assays were performed in triplicate with 
lymphocytes from three donors and in triplicate with 
CCRF-CEM cells.
Cell treatment. �oxoru�icin and idaru�icin were di-
luted in PBS and added to the cell suspension to give fi-
nal concentration in the range �.���� and �.�5�� µM for 
idaru�icin and doxoru�icin� respectively. Zinc salts were 
diluted in PBS and added to the sell suspension to give 
a final concentration �� µM. Each experiment contained 
three modes of exposure to anthracyclines: cells with 
anthracycline �doxoru�icin or idaru�icin� only� and an-
thracycline with zinc salt — ZnSO� and ZnCl�� separately. 
Cells were incu�ated for � h at ��ºC. Each experiment 
included a positive control� which was hydrogen perox-
ide at �� µM for �� min on ice.
Comet assay. The comet assay in the alkaline 
version was performed according to the procedure 
of Singh et al. [��]� with modification [��]. A freshly 
prepared suspension of the cells at the density 
��� ×��6 cells/ml in �.�5% LMP agarose dissolved 
in PBS was spread on microscope slides precoated 
previously with �.5% NMP agarose. The cells were 
lysed for � h in �°C in a solution of �.5 M NaCl� 
��� mM E�TA� �% Triton X-��� and �� mM Tris� pH ��. 
After lysis� the slides were placed in the comet assay 
electrophoresis system. �NA was allowed to un-
wind for �� min in the unwinding solution consisted 
of ��� mM NaOH and � mM E�TA� pH > ��. Electro-
phoresis was conducted in the electrophoresis �uffer 
containing �� mM NaOH and � mM E�TA� pH > ��� 
at the temperature not exceeding ��°C for �� min 
under �.�5 V/cm and �8 mA. The slides were washed 
in the water� drained and stained with � µg/ml �API 
and covered with cover slips. All steps mentioned were 
conducted under dimmed light.
Slides were o�served at ���× magnification 
in an Eclipse fluorescence microscope �Nikon� To-
kyo� Japan� equipped with COHU �9�� digital video 
camera �Cohu� San �iego� CA� USA� supplied with 
a UV� filter �lock� and connected to a personal com-
puter equipped with an image analysis system Lu-
cia — Comet v.�.5� �La�oratory Imaging� Praha� Czech 
Repu�lic�. Fifty randomly selected images from each 
experiment were measured. The �NA in comet tail was 
taken as an index of �NA damage. This parameter 
is positively correlated with the level of �NA �reakage 
and/or alkali la�ile sites and negatively correlated with 
the level of �NA cross-links [��]. Each experiment was 
performed at least � times. In the case of lymphocytes� 
each experiment was performed at least � times with 
the �lood from at least � different donors.
Data analysis. Values were expressed as mean ± 
S.E.M. from at least � separate experiments� i.e. data 
from � experiments were pooled and the statistical 
parameters were calculated. The data were ana-
lyzed using Statistica package �StatSoft� Tulsa� OK�. 
If no significant differences �etween variations were 
found� as assessed �y Snedecor-Fisher test� the dif-
ferences �etween means were evaluated �y applying 
the Student t test. Otherwise� the Cochran-Cox test 
was used.
RESULTS
We showed that the incu�ation of normal lympho-
cytes and leukemic cells with doxoru�icin caused a sig-
nificant �p < �.���� induction of �NA damage �Fig. ��. 
After incu�ation with doxoru�icin we o�served comets 
with shorter tails and with smaller amount of tail �NA 
with increasing concentration of the drug. We suggest 
that this effect may �e due to the induction of �oth �NA 
cross-links and its fragmentation �y the drug. The level 
of �NA damage induced �y doxoru�icin was higher 
in lymphocytes than in cancer cells. However� in the 
cancer cells we o�served a higher difference in the level 
of �NA damage �etween the cells incu�ated with the 
lowest and the highest concentration of doxoru�icin. 
Therefore� the processes leading to �NA damage — 
�NA fragmentation and �NA cross-links are more ef-
fective in cancer cells and for this reason we suggest 
that they are more sensitive to doxoru�icin than normal 
lymphocytes. Idaru�icin also induced �NA damage 
Experimental Oncology ��� �������� ���� ��ecem�er� ��9
in �oth types of cells� �ut it was more pronounced 
in cancer cells �p < �.���� �Fig. ��.
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Fig. 1. �NA damage� measured as the comet tail �NA in the 
comet assay� in lymphocytes �white� and CCRF-CEM cells �grey� 
incu�ated for � h at ��°C with doxoru�icin. The result of posi-
tive control ��� µM H�O� at �°C for �� min� was as follows: for 
lymphocytes �5.�� ± �.�� �p < �.���� and for CCRF-CEM cells 
��.55 ± �.�� �p < �.����
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Fig. 2. �NA damage� measured as the comet tail �NA in the 
comet assay� of lymphocytes �white� and CCRF-CEM cells �grey� 
incu�ated for � h at ��°C with idaru�icin. The result of posi-
tive control ��� µM H�O� at �°C for �� min� was as follows: for 
lymphocytes �5.�� ± �.�� �p < �.���� and for CCRF-CEM cells 
��.55 ± �.�� �p < �.����
We showed a different effect of zinc on the geno-
toxicity of doxoru�icin and idaru�icin in normal and 
cancer cells. The incu�ation of lymphocytes with 
zinc and doxoru�icin at �.�5 µΜ and � µΜ caused 
a significant decrease �p < �.�5� of �NA damage 
induced �y the anthracycline �Fig. �a�. In the case 
of CCRF-CEM cells we o�served a significant increase 
�p < �.���� of �NA damage induced �y doxoru�icin 
at the same concentrations in the presence of zinc 
�Fig. �b�. The addition of zinc to lymphocytes during 
incu�ation with idaru�icin caused a decrease of �NA 
damage �p < �.�5� induced �y this anti�iotic �Fig. �a�. 
On the contrary� the addition of zinc to CCRF-CEM 
cells evoked the significant increase of �NA damage 
�p < �.���� �Fig. �b�.
The via�ility of the cells was checked concurrently 
in all experiments at tested concentrations of anthracy-
clines and zinc salts �data not shown�. In the concen-
trations range of anthracyclines used in all experiments 
the via�ility of �oth types of cells was greater than 8�%. 
We o�served the greatest decrease in the cell via�ility 
in the case of CCRF-CEM cells incu�ated with idaru-
�icin and zinc salts. The via�ility of CCRF-CEM cells 
was 6�.� ± �.�% �p < �.���� in cell samples incu�ated 
with idaru�icin and ZnCl�.
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Fig. 3. �NA damage� measured as the comet tail �NA in the comet 
assay� of lymphocytes �a� and CCRF-CEM cells �b� incu�ated for 
� h at �� °C with doxoru�icin in the presence of ZnCl� �light grey� and 
ZnSO� �dark grey�. The result of positive control ��� µM H�O� at � °C for 
�� min� was as follows: for lymphocytes �5.68 ± �.�� �p < �.���� 
and for CCRF-CEM 9.�5 ± �.�� �p < �.����
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Fig. 4. �NA damage� measured as the comet tail �NA in the comet 
assay� of lymphocytes �a� and CCRF-CEM cells �b� incu�ated for 
� h at �� °C with idaru�icin in the presence of ZnCl� �light grey� and 
ZnSO� �dark grey�. The result of positive control ��� µM H�O� at � °C for 
�� min� was as follows: for lymphocytes ��.88 ± �.�� �p < �.���� 
and for CCRF-CEM cells ��.�6 ± �.�� �p < �.����
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DISCUSSION
Anthracyclines� including doxoru�icin and idaru�i-
cin are drugs applied in haematological malignancies. 
Both anti�iotics display antitumor properties through 
a num�er of molecular pathways. Both act as topoisom-
erase II poisons and possess mutagenic and recom�i-
nagenic properties [�5]. Topoisomerase II generates 
transient dou�le strand �reaks in �NA. Anthracyclines 
intercalate into �NA and pertur� the re-ligation step 
of topoisomerase II resulting in the formation of the 
ternary drug-�NA-topoisomerase II clea va�le com-
plex. This reaction results to a fragmentation of �NA 
[�6]. Anthracyclines can also generate adducts with 
�NA. It was shown that doxoru�icin� activated �y the 
endogenous formaldehyde to an active Schiff �ase� 
was a�le to form monoadducts within the 5`-GCN-�` 
sequences [��]. �oxoru�icin can also induce cross-
links in �NA [�9] and inhi�it the �NA methyltransferase 
�NMT� [��]. Moreover� anthracyclines can generate 
free radicals through activation �y a num�er of cellular 
oxydoreductases. Generation of free radicals is con-
sidered as one of the major mechanisms of anthracy-
clines cyto- and genotoxicity [�8]. Genotoxic action 
of anticancer drugs in normal tissues may lead to the 
induction of secondary malignancies; therefore� the 
pro�lem of the identification of mechanism�s� of such 
action is justified.
Treatment with zinc adjuvant is hypothesized to ac-
celerate recovery from ALL� and in conjunction with 
chemotherapy� might cure ALL [9]. Not any side effect 
of zinc or chemotherapy assisted �y zinc was reported 
and the element is considered as an agent to improve 
the patient’s overall a�ility to withstand toxic effects 
of chemotherapy [9]. In the present work� we deter-
mined the effect of zinc on genotoxicity of doxoru�icin 
and idaru�icin in normal lymphocytes and CCRF-CEM 
cells. To study �NA damage the alkaline comet assay 
was used. It is a sensitive and relatively inexpensive 
and noninvasive technique used for the detection 
of �NA damage and repair. �NA damage detected 
�y the alkaline comet assay includes single-strand 
�reaks �SSBs�� alkali la�ile sites �e.g.� apurinic/apy-
rimidinic �AP� sites�� dou�le-strand �reaks ��SBs� and 
modified �ases as well as �NA-�NA and �NA-protein 
cross-links. One of the major advantages of this as-
say is the capacity to analyze �NA damage and repair 
in individual cells. Furthermore� small num�ers of cells 
are required for this assay.
Previously� we showed that zinc did not induce 
�NA damage in normal cells� �ut did so in cancer 
cells of human myelogenous leukemia �K56� cell 
line� [�9]. We o�served a key difference �etween the 
action of zinc in normal and cancer cells in the pres-
ence of H�O�� since the element exerted a protective 
effect against cyto- and genotoxic action of H�O� in the 
former� whereas it increased such action in the latter. 
Moreover� we o�served that zinc inhi�ited the repair 
of �NA damage induced �y H�O� in cancer cells [�9].
Our results suggest a significant difference 
�etween normal and cancer cells in �NA damage 
extent induced �y anthracyclines� doxoru�icin and 
idaru�icin in the presence of zinc. Cancer cells ex-
hi�ited a significant increase of �NA damage in the 
presence of zinc �Fig. �b, �b�� while no such effect 
was o�served in lymphocytes �Fig. �a, �a�. Zinc can 
�e active as a modulator of cellular oxidative defense 
[��] and the addition of zinc may decrease prooxida-
tive action of anthracyclines. It was shown that some 
cancer cell lines were sensitive to external zinc and the 
addition of zinc could distur� a proliferation� trigger 
senescence or induce apoptosis in these cells [��]. 
Our results suggest that zinc may protect normal cells 
against the �NA-damaging action of anthracyclins and 
increase this action in leukemic cells. Therefore� zinc 
can �e useful in ALL chemotherapy as a modulator 
of drug genotoxicity.
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